A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)

NCT07593144 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: FS-207

Sponsor

Foresight Therapeutics (Hefei) Co., Ltd.